Large Cap Biopharma Stocks Review Ongoing Through Q1 Earnings

Small and Mid-Caps Outperform Large Caps YTD: XBI up 21 % YTD vs IBB up 8.19%

QQQ up 27%.

Rally emerging today on oversold condition in biotech.

We will update this valuation review since the political onslaught and sell-off from drug pricing politics. We can start with prices and valuations from our Large Cap Biopharma Performance post on Jan 1, 2019. A more detailed  update will be posted at the end of the week 4/27.

Here are some brief takeaways since the recent sell-off and a big 25% S&P move in 2019. As of mid-day trading here are prices and note that many large caps are up today: BMY, BIIB, GILD. Note that Bristol Myers (BMY) acquired Celgene. Earnings were out today for ABBV, ALXN, BMY.

  • Many large caps are down or flat YTD with big losers: ABBV, BIIB, BMY.
  • Notable winners :ALXN,CELG,VRTX.
  • IBB from $96.43 to $106.52.
  • XBI from $71.75 to $86.29.
  • XLV $86.46 to $87.94.

Large cap biopharma stocks near 52 week lows are: ABBV,AMGN, BMY, GILD. Closest to 52 week highs are: ALXN, CELG, MRK, RHHBY.

Here is a similar review for Large Cap Biopharma done two years ago in January 2017.



Pin It on Pinterest